IDH2 and central nervous system cancer: Suchorska et al assessed 300 patients with WHO grade II‐IV gliomas, grouped according to IDH1/2 mutation and 1p/19q codeletion, and showed that dynamic FET PET may provide further prognostic information in IDH1/IDH2 mutant diffuse gliomas, independent of WHO grading.72